Evaluation, Treatment, and Training for Patients With Blood Disorders

This protocol is designed to allow the evaluation, follow up, and standard medical care of
patients (and when appropriate, their stem cell donor) with bone marrow failure states,
cytopenias, metastatic solid tumors, or hematologic malignancies not currently entered on an
active NHLBI protocol or not being screened for an active NHLBI research protocol. Its
purpose is to allow investigation into the hematologic problems of these patients for the
primary purpose of teaching and furthering general hematologic knowledge. The ability to
evaluate and treat patients with a wide variety of hematologic disease is critical to
maintaining our accreditation as a hematology fellowship program and training our fellows to
be competent hematologists, as well as for keeping all staff, including senior staff,
up-to-date and familiar with the evaluation and treatment of patients with a wide spectrum of
hematologic disease. It also allows the NHLBI investigators to evaluate patients referred
with rare or as yet undiagnosed hematologic problems, both potentially benefiting the patient
and stimulating new research directions for the NHLBI in the future. Periodic follow-up and
treatment of patients previously entered on NHLBI protocols in order to monitor the long-term
course of the underlying hematologic state and the consequences of experimental treatments is
also required for fellowship training, and for maintenance of good referral relationships
with patients and their physicians.

- INCLUSION CRITERIA:

Patients (and when appropriate the patient's stem cell donor) may be entered on this
protocol at the discretion of the Principal and/or Associate Investigators if :

An investigator decides that it is in the best interest of the patient/donor and the Branch
for the patient to be enrolled in this protocol while awaiting a decision on eligibility
for other protocols; or after enrollment on another protocol, or to allow careful
evaluation of patients with unique or rare disorders of direct interest to the Branch; or
with more common disorders for fellowship teaching purposes.

The patient or the patient's guardian is capable of informed consent and signs the consent
form. The consent form will be signed by parents or guardians of patients under the age of
18.

Age greater than or equal to 2 and weight greater than 12 kg.